¿Emergencia médica?¿Emergencia? Llame al 911. Salas de emergencias más cercanasEmergencias cercanas

Medicamento con receta

Doravirine, lamivudine, and tenofovir disoproxil fumarate

Clase de medicamento: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

La «clase farmacológica establecida» de la FDA: el grupo de medicamentos que actúan de forma parecida. Se muestra en inglés, como la publica la FDA.

Datos oficiales de la FDA, no son consejos

Todo lo que aparece aquí viene de la Administración de Alimentos y Medicamentos de los EE. UU. (FDA): la etiqueta del medicamento, el directorio NDC, Drugs@FDA, los informes de retiros y la lista de escasez. Cada dato indica su fuente y su fecha.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

En una emergencia, llame al 911. Si alguien pudo haber tomado demasiado de un medicamento, llame a la Línea de Ayuda para Envenenamientos (Poison Help): 1‑800‑222‑1222.

Doravirine, lamivudine, and tenofovir disoproxil fumarate: datos clave

Clase de medicamento
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Se usa para
En inglés, según la etiqueta: DELSTRIGO ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg … (fuente)
Con receta o sin receta
Con receta (Rx)
Hay genérico
La FDA no indica genérico
Costo típico para la farmacia
$93.07 por tableta (doravirine 100 mg · lamivudine 300 mg · tenofovir disoproxil fumarate 300 mg; NADAC)
Último retiro de la FDA
Ninguno registrado

Fuentes: etiqueta de la FDA (8 de julio de 2026); directorio NDC de la FDA (13 de noviembre de 2026); CMS NADAC (11 de noviembre de 2026); informes de retiros de la FDA (10 de noviembre de 2026). No es un consejo médico.

Respuestas rápidas

¿Para qué se usa Doravirine, lamivudine, and tenofovir disoproxil fumarate?
La etiqueta aprobada por la FDA (Delstrigo, Merck Sharp & Dohme LLC, 8 de julio de 2026) dice, en inglés: “DELSTRIGO ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions …” Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Cuáles son los efectos secundarios de Doravirine, lamivudine, and tenofovir disoproxil fumarate?
La sección «Adverse Reactions» (reacciones adversas) de la etiqueta de la FDA (Delstrigo, Merck Sharp & Dohme LLC, 8 de julio de 2026) comienza así, en inglés: «The following adverse reactions are discussed in other sections of the labeling: Skin and Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Severe Acute Exacerbation of Hepatitis B in people with concomitant HIV-1 and HBV [see Warnings and Precautions (5.2)] New Onset or Worsening Renal Impairment [see Warnings and Precautions (5.3)] Bone Loss and Mineralization Defects [see Warnings and Precautions (5.5)] Immune Reconstitution Syndrome [see Warnings and Precautions (5.6)] Most common adverse reactions (incidence greater than or equal to 5%, all grades) are dizziness, nausea, and abnormal dreams.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Qué interacciones tiene Doravirine, lamivudine, and tenofovir disoproxil fumarate?
La sección «Drug Interactions» (interacciones) de la etiqueta de la FDA (Delstrigo, Merck Sharp & Dohme LLC, 8 de julio de 2026) comienza así, en inglés: «Because DELSTRIGO is a complete regimen, co-administration with other antiretroviral medications for treatment of HIV-1 infection is not recommended. (7.1) Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Doravirine, lamivudine, and tenofovir disoproxil fumarate tiene una advertencia en recuadro?
Sí. La etiqueta de la FDA de Delstrigo tiene una advertencia en recuadro («WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B»), la advertencia más seria de la FDA. Léala en la etiqueta completa y pregunte a su farmacéutico.
¿Hay escasez de Doravirine, lamivudine, and tenofovir disoproxil fumarate?
La FDA no indica una escasez actual para los productos de este medicamento (datos de la FDA del 13 de noviembre de 2026).
¿Se ha retirado del mercado Doravirine, lamivudine, and tenofovir disoproxil fumarate?
No aparece ningún retiro vinculado a los productos de este medicamento en los informes de la FDA que usamos.
¿Quién fabrica Doravirine, lamivudine, and tenofovir disoproxil fumarate?
1 empresa tiene productos con receta de Doravirine, lamivudine, and tenofovir disoproxil fumarate en el directorio NDC de la FDA, entre ellas Merck Sharp & Dohme LLC.

Para qué se usa Doravirine, lamivudine, and tenofovir disoproxil fumarate

Cita de la sección «Indications and Usage» (indicaciones y uso) de la etiqueta aprobada por la FDA. Se muestra en inglés, tal como la publica la FDA.

DELSTRIGO ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions …

— Etiqueta de la FDA: Delstrigo, Merck Sharp & Dohme LLC, vigente desde el 8 de julio de 2026. Leer la etiqueta completa en DailyMed →

Etiqueta citada: la de la presentación más común (tablet, film coated, oral), Delstrigo, Merck Sharp & Dohme LLC; abarca 1 producto del directorio NDC de la FDA. Las citas sobre efectos secundarios, interacciones, dosis y embarazo de abajo vienen de esta misma etiqueta.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

Advertencia en recuadro

La advertencia en recuadro («caja negra») es la advertencia más seria de la FDA en la etiqueta de un medicamento, para riesgos graves o mortales.

Esta etiqueta tiene una advertencia en recuadro. Su título: WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B. Leerla en la etiqueta completa →

Doravirine, lamivudine, and tenofovir disoproxil fumarate: lo que dice la advertencia en recuadro

Cita de la advertencia en recuadro (Boxed Warning) de la etiqueta aprobada por la FDA. Se muestra en inglés.

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in people with concomitant HIV-1 and HBV who have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), which are components of DELSTRIGO. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue DELSTRIGO.

Leer más de esta sección

If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.2)]. WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B (HBV) have been reported in people with concomitant HIV-1 and HBV who have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), two of the components of DELSTRIGO. Closely monitor hepatic function in these patients. If appropriate, initiation of anti-hepatitis B therapy may be warranted. (5.2)

— Etiqueta de la FDA: Delstrigo, Merck Sharp & Dohme LLC, vigente desde el 8 de julio de 2026. Leer la etiqueta completa en DailyMed →

Efectos secundarios de Doravirine, lamivudine, and tenofovir disoproxil fumarate

Cita de la sección «Adverse Reactions» (reacciones adversas) de la etiqueta aprobada por la FDA. Se muestra en inglés. Avise a su médico de cualquier efecto secundario que le preocupe.

The following adverse reactions are discussed in other sections of the labeling: Skin and Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Severe Acute Exacerbation of Hepatitis B in people with concomitant HIV-1 and HBV [see Warnings and Precautions (5.2)] New Onset or Worsening Renal Impairment [see Warnings and Precautions (5.3)] Bone Loss and Mineralization Defects [see Warnings and Precautions (5.5)] Immune Reconstitution Syndrome [see Warnings and Precautions (5.6)] Most common adverse reactions (incidence greater than or equal to 5%, all grades) are dizziness, nausea, and abnormal dreams.

Leer más de esta sección

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Adults with No Antiretroviral Treatment History The safety assessment of DELSTRIGO is based on Week 96 data from two Phase 3, randomized, international, multicenter, double-blind, active-controlled trials. A total of 747 participants received doravirine either as the single entity in combination with other antiretroviral drugs as background regimens (n=383) or as the fixed-dose DELSTRIGO (n=364), and a total of 747 participants were randomized to control arms. In DRIVE-AHEAD (Protocol 021), 728 adult participants received either DELSTRIGO (n=364) or EFV/FTC/TDF once daily (n=364). By Week 96, 3% in the DELSTRIGO group and 7% in the EFV/FTC/TDF group had adverse events leading to discontinuation of study medication. Adverse reactions reported in greater than or equal to 5% of participants in any treatment group in DRIVE-AHEAD are presented in Table 1. Table 1: Adverse Reactions Frequencies of adverse reactions are based on all adverse events attributed to trial drugs by the investigator. (All Grades) Reported in ≥5% No adverse reactions of Grade 2 or higher (moderate or severe) occurred in ≥2% of participants treated with DELSTRIGO. of Participants in Any Treatment Group in Adults with No Antiretroviral Treatment History in DRIVE-AHEAD (Week 96) DELSTRIGO Once Daily N=364 EFV/FTC/TDF Once Daily N=364 Dizziness 7% 32% Nausea 5% 7% Abnormal Dreams 5% 10% Headache 4% 5% Insomnia 4% 5% Diarrhea 4% 6% Somnolence 3% 7% Rash Rash: includes rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic. 2% 12% The majority (66%) of adverse reactions associated with DELSTRIGO occurred at severity Grade 1 (mild). Neuropsychiatric Adverse Events For DRIVE-AHEAD, the analysis of participants with neuropsychiatric adverse events by Week 48 is presented in Table 2. The proportion of participants who reported one or more neuropsychiatric adverse events was 24% and 57% in the DELSTRIGO and EFV/FTC/TDF groups, respectively. A statistically significantly lower proportion of DELSTRIGO-treated participants compared to EFV/FTC/TDF-treated participants reported neuropsychiatric adverse events by Week 48 in the three pre-specified categories of dizziness, sleep disorders and disturbances, and altered sensorium.

Tabla de la etiqueta
DELSTRIGO Once Daily N=364EFV/FTC/TDF Once Daily N=364
Dizziness7%32%
Nausea5%7%
Abnormal Dreams5%10%
Headache4%5%
Insomnia4%5%
Diarrhea4%6%
Somnolence3%7%
RashRash: includes rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic.2%12%

— Etiqueta de la FDA: Delstrigo, Merck Sharp & Dohme LLC, vigente desde el 8 de julio de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Interacciones de Doravirine, lamivudine, and tenofovir disoproxil fumarate

Cita de la sección «Drug Interactions» (interacciones) de la etiqueta aprobada por la FDA. Se muestra en inglés. Dígale a su farmacéutico todos los medicamentos, vitaminas y productos herbales que toma.

Because DELSTRIGO is a complete regimen, co-administration with other antiretroviral medications for treatment of HIV-1 infection is not recommended. (7.1) Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions.

Leer más de esta sección

(4, 5.4, 7) 7.1 Concomitant Use with Other Antiretroviral Medications Because DELSTRIGO is a complete regimen for the treatment of HIV-1 infection, co-administration with other antiretroviral medications for treatment of HIV-1 infection is not recommended. Information regarding potential drug-drug interactions with other antiretroviral medications is not provided. 7.2 Effect of Other Drugs on DELSTRIGO Co-administration of DELSTRIGO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce DELSTRIGO efficacy [see Contraindications (4), Warnings and Precautions (5.4), and Clinical Pharmacology (12.3)]. Co-administration of DELSTRIGO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows the significant drug interactions with the components of DELSTRIGO. The drug interactions described are based on studies conducted with either DELSTRIGO or the components of DELSTRIGO as individual agents. Table 6: Drug Interactions with DELSTRIGO This table is not all-inclusive Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment ↑ = increase, ↓ = decrease All other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide ↓ doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week cessation period is recommended prior to initiation of DELSTRIGO. Anticonvulsants carbamazepine oxcarbazepine phenobarbital phenytoin ↓ doravirine Co-administration is contraindicated with these anticonvulsants. At least a 4-week cessation period is recommended prior to initiation of DELSTRIGO. Antimycobacterials rifampin The interaction between doravirine and the concomitant drug was evaluated in a clinical study. rifapentine ↓ doravirine Co-administration is contraindicated with rifampin or rifapentine. At least a 4-week cessation period is recommended prior to initiation of DELSTRIGO. rifabutin ↓ doravirine If DELSTRIGO is co-administered with rifabutin, one tablet of doravirine (PIFELTRO) should be taken approximately 12 hours after the dose of DELSTRIGO [see Dosage and Administration (2.4)]. Cytotoxic Agents mitotane ↓ doravirine Co-administration is contraindicated with mitotane. At least a 4-week cessation period is recommended prior to initiation of DELSTRIGO. Hepatitis C Antiviral Agents ledipasvir/sofosbuvir sofosbuvir/velpatasvir ↑ tenofovir Monitor for adverse reactions associated with TDF. Herbal Products St. John's wort ↓ doravirine Co-administration is contraindicated with St. John's wort. At least a 4-week cessation period is recommended prior to initiation of DELSTRIGO.

— Etiqueta de la FDA: Delstrigo, Merck Sharp & Dohme LLC, vigente desde el 8 de julio de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Dosis de Doravirine, lamivudine, and tenofovir disoproxil fumarate

Cita de la sección «Dosage and Administration» (dosis y administración) de la etiqueta aprobada por la FDA. Se muestra en inglés. Su dosis es la que le receta su médico: no la cambie por su cuenta.

Testing: Prior to or when initiating DELSTRIGO, test for HBV infection. Prior to or when initiating DELSTRIGO, and during treatment with DELSTRIGO, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.

Leer más de esta sección

(2.1) Recommended dosage: One tablet taken orally once daily with or without food in adults and pediatric patients weighing at least 35 kg. (2.2) Renal impairment: Not recommended in patients with estimated creatinine clearance below 50 mL per minute. (2.3) Dosage adjustment with rifabutin: Take one tablet of DELSTRIGO once daily, followed by one tablet of doravirine 100 mg (PIFELTRO) approximately 12 hours after the dose of DELSTRIGO. (2.4) 2.1 Testing When Initiating and During Treatment with DELSTRIGO Prior to or when initiating DELSTRIGO, test patients for HBV infection [see Warnings and Precautions (5.2)]. Prior to or when initiating DELSTRIGO, and during treatment with DELSTRIGO, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus [see Warnings and Precautions (5.3)]. 2.2 Recommended Dosage DELSTRIGO is a fixed-dose combination product containing 100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF. The recommended dosage of DELSTRIGO in adults and pediatric patients weighing at least 35 kg is one tablet taken orally once daily with or without food [see Clinical Pharmacology (12.3)]. 2.3 Renal Impairment Because DELSTRIGO is a fixed-dose combination tablet and the dosage of lamivudine and TDF cannot be adjusted, DELSTRIGO is not recommended in patients with estimated creatinine clearance less than 50 mL/min [see Warnings and Precautions (5.3) and Use in Specific Populations (8.6)]. 2.4 Dosage Adjustment with Rifabutin If DELSTRIGO is co-administered with rifabutin, take one tablet of DELSTRIGO once daily, followed by one tablet of doravirine 100 mg (PIFELTRO) approximately 12 hours after the dose of DELSTRIGO for the duration of rifabutin co-administration [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].

— Etiqueta de la FDA: Delstrigo, Merck Sharp & Dohme LLC, vigente desde el 8 de julio de 2026. Leer la etiqueta completa en DailyMed →

Doravirine, lamivudine, and tenofovir disoproxil fumarate en el embarazo

Cita de la parte sobre embarazo (Pregnancy) de la etiqueta aprobada por la FDA. Se muestra en inglés. Pregunte a su médico antes de tomar cualquier medicamento si está embarazada o planea estarlo.

Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to DELSTRIGO during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263. Risk Summary There is insufficient prospective pregnancy data from the APR to adequately assess the risk of birth defects and miscarriage.

Leer más de esta sección

Doravirine use in individuals during pregnancy has not been evaluated; however, lamivudine and TDF use during pregnancy has been evaluated in a limited number of individuals reported to the APR. Available data from the APR show no difference in the overall risk of major birth defects for lamivudine and TDF compared with the background rate for major birth defects of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) (see Data). The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in the clinically recognized pregnancies in the U.S. general population is 15-20%. Methodological limitations of the APR include the use of MACDP as the external comparator group. The MACDP population is not disease-specific, evaluates individuals and infants from the limited geographic area, and does not include outcomes for births that occurred at less than 20 weeks gestation. In animal reproduction studies, oral administration of lamivudine to pregnant rabbits during organogenesis resulted in embryolethality at systemic exposure (AUC) similar to the recommended clinical dose; however, no adverse development effects were observed with oral administration of lamivudine to pregnant rats during organogenesis at plasma concentrations (C max) 35 times the recommended clinical dose. No adverse developmental effects were observed when doravirine and TDF were administered separately at doses/exposures ≥8 (doravirine) and ≥14 (TDF) times those of the recommended human dose (RHD) of DELSTRIGO (see Data). Data Human Data Lamivudine: The APR has received a total of over 13,000 prospective reports with follow-up data of possible exposure to lamivudine-containing regimens; over 5,900 reports in the first trimester; over 5,600 reports in the second trimester; and over 1,800 reports in the third trimester. Birth defects occurred in 170 of 5,472 (3.1%, 95% CI: 2.7% to 3.6%) live births for lamivudine-containing regimens (first trimester exposure); and 218 of 7,513 (2.9%, 95% CI: 2.5% to 3.3%) live births for lamivudine-containing regimens (second/third trimester exposure). Among pregnant mothers in the U.S. reference population, the background rate of birth defects is 2.7%. There was no association between lamivudine and overall birth defects observed in the APR. TDF: The APR has received a total of over 7,000 prospective reports with follow-up data of possible exposure to tenofovir disoproxil-containing regimens; over 5,100 reports in the first trimester; over 1,300 reports in the second trimester; and over 600 reports in the third trimester.

— Etiqueta de la FDA: Delstrigo, Merck Sharp & Dohme LLC, vigente desde el 8 de julio de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Cuándo no se debe usar Doravirine, lamivudine, and tenofovir disoproxil fumarate

Cita de la sección «Contraindications» (contraindicaciones) de la etiqueta aprobada por la FDA. Se muestra en inglés.

DELSTRIGO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of DELSTRIGO [see Warnings and Precautions (5.4), Drug Interactions (7.2), and Clinical Pharmacology (12.3)].

Leer más de esta sección

These drugs include, but are not limited to, the following: - the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin - the androgen receptor inhibitor enzalutamide - the antimycobacterials rifampin, rifapentine - the cytotoxic agent mitotane - St. John's wort (Hypericum perforatum) DELSTRIGO is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. DELSTRIGO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of DELSTRIGO. (4) DELSTRIGO is contraindicated in patients with a previous hypersensitivity reaction to lamivudine.

— Etiqueta de la FDA: Delstrigo, Merck Sharp & Dohme LLC, vigente desde el 8 de julio de 2026. Leer la etiqueta completa en DailyMed →

Sobredosis de Doravirine, lamivudine, and tenofovir disoproxil fumarate

Cita de la sección «Overdosage» (sobredosis) de la etiqueta aprobada por la FDA. Se muestra en inglés. Si alguien pudo haber tomado demasiado, llame a Poison Help al 1-800-222-1222 (o al 911 en una emergencia).

No data are available on overdose of DELSTRIGO in patients and there is no known specific treatment for overdose with DELSTRIGO. If overdose occurs, the patient should be monitored and standard supportive treatment applied as required. Doravirine: There is no known specific treatment for overdose with doravirine.

Leer más de esta sección

Lamivudine: Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event. TDF: TDF is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of TDF, a 4-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.

— Etiqueta de la FDA: Delstrigo, Merck Sharp & Dohme LLC, vigente desde el 8 de julio de 2026. Leer la etiqueta completa en DailyMed →

Presentaciones y vía de administración

Formas farmacéuticasTableta, recubierta con película
VíaOral
Productos con receta1 en el directorio NDC de la FDA
Nombres de marcaDelstrigo

Lo que pagan las farmacias (NADAC)

El Costo Promedio Nacional de Adquisición de Medicamentos (NADAC, por sus siglas en inglés) es el precio promedio que pagaron las farmacias minoristas de los EE. UU. por comprar una unidad de un medicamento (una tableta, un mL o un gramo), según una encuesta mensual de facturas de farmacias de los Centros de Servicios de Medicare y Medicaid (CMS). Los programas estatales de Medicaid lo usan para pagar a las farmacias.

Este no es el precio que usted paga. Lo que usted paga depende de su seguro médico (copago o coseguro), de su farmacia y de los descuentos, y las farmacias también cobran por despachar una receta. Pregunte a su farmacéutico o a su plan de salud cuál será su precio.

NADAC por unidad de Doravirine, lamivudine, and tenofovir disoproxil fumarate, por concentración y forma
Concentración y formaGenérico o de marcaPagan las farmacias
doravirine 100 mg · lamivudine 300 mg · tenofovir disoproxil fumarate 300 mg
tableta, recubierta con película
De marca: Delstrigo $93.07 por tableta

Lista NADAC del 11 de noviembre de 2026; estos precios rigen desde el 21 de octubre de 2026. Solo se muestra cuando el código NDC de un envase coincide exactamente con la lista NADAC, y solo para esa concentración y forma: no se promedia entre concentraciones. Las concentraciones y formas que no aparecen aquí no tienen precio NADAC.

Fuente: conjunto de datos «NADAC (National Average Drug Acquisition Cost) 2026», data.medicaid.gov (CMS) →

Empresas que tienen este medicamento

Empresas en el directorio NDC de la FDA: la empresa que aparece en el envase (fabricante o distribuidor), con su número de productos con receta.

Historial de aprobación de la FDA

  • NDA: Solicitud de nuevo medicamento (NDA): así se aprueba un medicamento nuevo, normalmente de marca.
Solicitudes de marca y biológicas
SolicitudPatrocinadorAprobadaCambios aprobados después
NDA210807
DELSTRIGO
Msd Merck Co30 de agosto de 2018 7, el último 29 de septiembre de 2026
2026: Etiquetado · 2025: Etiquetado · 2025: Etiquetado

Escasez

La lista de escasez de la FDA no incluye estos productos.

Base de datos de escasez de medicamentos de la FDA →

Retiros del mercado

No aparece ningún retiro vinculado a estos productos (por su código NDC) en los informes de la FDA.

Identificadores oficiales

RxCUI (RxNorm)2055813, 2055815
ID (SPL set ID) de la etiqueta citadacd1e9f84-607a-46d3-b01e-2736018d67b6
Etiquetas de la FDA (SPL)1
Solicitudes de la FDANDA210807
Principios activos (FDA)DORAVIRINE / LAMIVUDINE / TENOFOVIR DISOPROXIL

Siguientes pasos

Fuentes

  1. Etiqueta aprobada por la FDA en DailyMed (Biblioteca Nacional de Medicina) — Delstrigo, Merck Sharp & Dohme LLC, vigente desde el 8 de julio de 2026; vía openFDA, datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  2. NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  3. Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  4. Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026
  5. Drug shortages (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026

La FDA ofrece los datos de openFDA tal cual; pueden estar incompletos. Guíese siempre por la etiqueta que viene con su medicamento. Buscador de informes de retiros de la FDA →

Informar un error → · Información para fabricantes de medicamentos